Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection
Dolutegravir (DTG) + lamivudine (3TC) dual therapy regimen has entered the guidelines as a preferred first-line treatment regimen in antiretroviral treatment naïve individuals and as a switch regimen in cases with virologic suppression. Although clinical studies and real-life data suggest that virol...
שמור ב:
| Principais autores: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Infectious Diseases and Clinical Microbiology Specialty Society of Turkey
2022-12-01
|
| סדרה: | Mediterranean Journal of Infection, Microbes and Antimicrobials |
| נושאים: | |
| גישה מקוונת: | https://www.mjima.org/text.php?&id=356 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|